Elinogrel ( INN, USAN) was an experimental antiplatelet drug acting as a P2Y₁₂ inhibitor. Similarly to ticagrelor and in contrast to

clopidogrel Clopidogrel — sold under the brand name Plavix, among others — is an antiplatelet medication used to reduce the risk of heart disease and stroke in those at high risk. It is also used together with aspirin in heart attacks and following t ...

, elinogrel was a reversible inhibitor that acted fast and short (for about 12 hours), and it was not a

prodrug A prodrug is a medication or compound that, after intake, is metabolized (i.e., converted within the body) into a pharmacologically active drug. Instead of administering a drug directly, a corresponding prodrug can be used to improve how the drug ...

but pharmacologically active itself. The substance was used in form of its potassium salt,

intravenous Intravenous therapy (abbreviated as IV therapy) is a medical technique that administers fluids, medications and nutrients directly into a person's vein. The intravenous route of administration is commonly used for rehydration or to provide nutrie ...

ly for acute treatment and

orally The word oral may refer to: Relating to the mouth * Relating to the mouth, the first portion of the alimentary canal that primarily receives food and liquid **Oral administration of medicines ** Oral examination (also known as an oral exam or oral ...

for long-term treatment. Development was terminated in 2012.

History

The substance was originally developed by Portola Pharmaceuticals, with Phase II clinical trials conducted around 2008–2011. In February 2009, Novartis bought worldwide rights to develop it further, intending to conduct Phase III studies and commercialise the drug. The development of the drug was terminated in January 2012 by Novartis.

References

Abandoned drugs Adenosine diphosphate receptor inhibitors {{blood-drug-stub